ArticleNature communications2026
A DNA-based nanodevice senses purinergic signaling and drives an immune switch for resolving inflammation.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Purinergic signaling dysregulation (e.g., excessive extracellular ATP, exATP) plays a critical role in the pathology of inflammatory disorders, but current efforts in drug development for blocking purinergic receptors are unsatisfactory. Here, inspired by natural metabolite sensing/signaling system, we develop a DNA origami-based ATP-sensing nanodevice (ND) for fine-tuning purinergic signaling and immune homeostasis. This ND composes a tubular DNA origami equipped with ATP sensors and the catalytic subunits (ENPP1-CD73 pairs), which can sense high levels of exATP and then expose the catalytic subunits for metabolizing exATP to adenosine, thereby driving an immune switch from exATP-mediated proinflammatory signals to adenosine-mediated immunosuppressive signals. Further surface displaying of ND on the monocytes (ND@Monos) enables its active inflamed site-targeting to restore immunometabolic hemostasis and reduce inflammation in diverse models in vivo. This study highlights that design of metabolite-sensing NDs is a promising strategy for controlling the homeostasis of cell metabolism and the immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.